New combo therapy shows promise for rare blood cancer in younger patients
NCT ID NCT02858804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and whether maintenance therapy with rituximab and other drugs helps keep the disease from returning. The trial has been completed, and results focus on how long patients live without the cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shuhua Yi
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients